Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors

Overcoming the challenges associated with CD3+ T-cell redirection in cancer

(2021) Ajit Singh et al.   BRITISH JOURNAL OF CANCER

Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model

(2021) Floriana Cremasco et al.   PLoS One

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

(2021) Jim Middelburg et al.   Cancers

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

(2020) Wenyan Zhong et al.   BMC GENOMICS

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

(2020) Dimitris Skokos et al.   Science Translational Medicine

Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

(2020) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation

(2020) Danica Chiu et al.   Cancer Immunology Research

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor

(2020) Huilin Ma et al.   AAPS Journal

609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

(2020) B. Tran et al.   ANNALS OF ONCOLOGY

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

(2020) Seyed Samad Hosseini et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

(2020) Johannes Sam et al.   Frontiers in Oncology

Genomic correlates of response to immune checkpoint blockade

(2019) Tanya E. Keenan et al.   NATURE MEDICINE

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

(2019) Nathan D. Trinklein et al.   mAbs

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

(2019) Christina L. Zuch de Zafra et al.   CLINICAL CANCER RESEARCH

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

(2019) Horst-Dieter Hummel et al.   JOURNAL OF CLINICAL ONCOLOGY

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

(2019) Alison Crawford et al.   Science Translational Medicine

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

(2019) Christina Claus et al.   Science Translational Medicine

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

(2019) Veit Bücklein et al.   BLOOD

IFN-γ-induced chemokines are required for CXCR3-mediated T cell recruitment and anti-tumor efficacy of anti-HER2/CD3 bispecific antibody

(2018) Ji Li et al.   CLINICAL CANCER RESEARCH

4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses

(2018) Ashley V. Menk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Monomeric TCRs drive T cell antigen recognition

(2018) Mario Brameshuber et al.   NATURE IMMUNOLOGY

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

CD3-bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory

(2018) Hreinn Benonisson et al.   MOLECULAR CANCER THERAPEUTICS

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

IL-2 Modulates the TCR Signaling Threshold for CD8 but Not CD4 T Cell Proliferation on a Single-Cell Level

(2017) Byron B. Au-Yeung et al.   JOURNAL OF IMMUNOLOGY

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

(2017) J Duell et al.   LEUKEMIA

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

(2017) Takahiro Ishiguro et al.   Science Translational Medicine

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models

(2017) Aran F. Labrijn et al.   Scientific Reports

CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells

(2017) Mireya Paulina Velasquez et al.   Cancer Immunology Research

Entire CD3ε, δ and γ humanized mouse to evaluate human CD3–mediated therapeutics

(2017) Otoya Ueda et al.   Scientific Reports

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions

(2016) Matthias Klinger et al.   IMMUNOLOGICAL REVIEWS

Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffoldin Vitro

(2016) Ling Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

(2016) Maria-Elisabeth Goebeler et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity

(2015) Ming-Ru Wu et al.   JOURNAL OF IMMUNOLOGY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

(2015) Eric J. Smith et al.   Scientific Reports

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

(2014) T. T. Junttila et al.   CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Differential Kinetics of Antigen Dependency of CD4+ and CD8+ T Cells

(2014) H. Rabenstein et al.   JOURNAL OF IMMUNOLOGY

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

(2014) Hiroshi Yano et al.   Journal of Translational Medicine

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody

(2013) B. D. Choi et al.   Cancer Immunology Research

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

T Cell Receptors are Structures Capable of Initiating Signaling in the Absence of Large Conformational Rearrangements

(2012) Ricardo A. Fernandes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells

(2012) A. Feldmann et al.   JOURNAL OF IMMUNOLOGY

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection

(2012) M. A. Paley et al.   SCIENCE

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

(2010) J. N. Kochenderfer et al.   BLOOD

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY